Skip to main content

Market Overview

Citi Sees 26% Upside In TESARO On The Strength Of Trial Data

Citi Sees 26% Upside In TESARO On The Strength Of Trial Data

Shares of TESARO Inc (NASDAQ: TSRO) were trading higher by more than 12 percent early Monday morning after the company reported encouraging results from its niraparib Phase 3 NOVA clinical trial results.

The trial was designed to assess the progression free survival rate among 553 patients suffering from ovarian cancer. The clinical trial managed to successfully achieve its primary endpoint of demonstrating that niraparid treatment significantly prolonged the progression free survival rate.

Citi: Price Target Raised To $125

Robyn Karnauskas of Citi maintains a Buy rating on TESARO's stock with a price target boosted to $125 from a previous $120 on Monday.

Karnauskas noted that TESARO reported as expected clinically meaningful benefits. The company is now expected to complete its NDA (New Drug Application) and MAA (Marketing Authorization Application) submissions for its therapy by the end of 2016.

Related Link: Wedbush Raises Tesaro Price Target From $107 To $139

The analyst commented on the trial results, saying, "At ESMO, the company reported PFS of 20.9 mos (vs. 11.0 mo placebo) in HRD+ somatic BRCA pts. However, given the 12.9 mo. PFS in the total HRD+ pts (vs. 3.8 mo placebo, HR 0.38) and the 9.3 mo PFS (vs.3.9 placebo, HR 0.45) seen in HRD+ wtBRCA patients, we believe that all HRD+ patients are seeing clinically meaningful benefits. We note that 37 percent of patients are still on therapy at 18 months. Our model assumes 100 percent probability and 10 mo duration of therapy for 2ndline."

Furthermore, the analyst added, "In addition to these patients not having other treatment options, we believe that 1) 3.1 months over placebo which increases platinum free interval and gives patients time to resolve platinum related thrombocytopenia, 2) 42 percent risk reduction, and 3) 20 percent patients still on treatment at 18 months indicate clinically meaningful benefit to HRD-ve patients. We update our model with 100 percent probability of success in 2ndline."

At last check, TESARO was up 21.11 percent at $120.21.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for TSRO

Dec 2018BarclaysDowngradesOverweightEqual-Weight
Dec 2018WedbushDowngradesOutperformNeutral
Dec 2018GuggenheimDowngradesBuyNeutral

View More Analyst Ratings for TSRO
View the Latest Analyst Ratings


Related Articles (TSRO)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

FSRMorgan StanleyMaintains40.0
MEDDA DavidsonMaintains302.0
VICRBWS FinancialMaintains120.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at